Related Experiment Video
Updated: Mar 25, 2026
09:44
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
3.5K
[Case-control based study between polymorphisms in the adiponectin gene and polycystic ovary syndrome]
Wenjuan Zhang1, Xingguo Wu, Mingde Ding
1Center for Reproductive Medicine, Affiliated Hospital of Taishan Medical University, Taian 271000, China.
Zhonghua Fu Chan Ke Za Zhi
|February 19, 2016
Summary
Genetic variations in the adiponectin gene (ADIPOQ) were studied in relation to polycystic ovary syndrome (PCOS). Specific single nucleotide polymorphisms (SNPs) rs17300539 and rs1501299 were found to be associated with an increased risk of developing PCOS.
Area of Science:
- Genetics
- Endocrinology
- Reproductive Medicine
Background:
- Polycystic ovary syndrome (PCOS) is a complex endocrine disorder.
- Adiponectin (ADIPOQ) plays a role in metabolic and reproductive functions.
- Single nucleotide polymorphisms (SNPs) in ADIPOQ may influence PCOS susceptibility.
Purpose of the Study:
- To investigate the frequencies of four ADIPOQ gene SNPs (rs17300539, rs12495941, rs2241766, rs1501299).
- To determine the association between these ADIPOQ SNPs and the pathogenesis of PCOS.
Main Methods:
- Genomic DNA was extracted from 207 women with PCOS and 192 controls.
- PCR amplification and direct sequencing were used to analyze four specific ADIPOQ SNPs.
- Genotype and allele frequencies were compared between PCOS patients and controls.
Main Results:
- Significant differences in genotype and allele frequencies were observed for rs17300539 and rs1501299 between PCOS cases and controls.
- The AA genotype of rs17300539 and the CC genotype of rs1501299 were associated with an increased risk of PCOS.
- No significant associations were found for SNPs rs2241766 and rs12495941.
Conclusions:
- ADIPOQ gene variants rs17300539 and rs1501299 are associated with PCOS.
- These SNPs may represent susceptibility loci for PCOS.
- Further research is warranted to elucidate the precise mechanisms.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
67
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
02:07Oogenesis
71.2K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
71.2K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
125
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
125
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
111
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
111